Navigation Links
Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Women's Hall of Fame
Date:10/31/2008

NEW HAVEN, Conn., Oct. 31 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that President and CEO, Susan Froshauer, PhD, was honored last night by The Connecticut Women's Hall of Fame at their 15th Annual Gala & Induction Ceremony. As part of this year's event, a group of 15 women were recognized as members of the "New Century of Women in Science" along with four high school and college age students for their innovation and commitment to the advancement of the scientific and engineering fields.

This year's inductees included Nobel Prize Winner Barbara McClintock, PhD, world-renowned Yale University neuroscientist Patricia Goldman-Rakic, PhD, Yale University Sterling Professor of Molecular Biophysics Joan Steitz, PhD, and leading cell biologist Jewel Plummer Cobb, PhD. Previous inductees include Florence Wald, the founder of hospice care in the U.S., Emeline Roberts Jones, DDS, the first female dentist in the U.S., Hellen Keller and Katharine Hepburn.

"I am humbled to be a part of this collective group of women pioneers and to have been recognized by my peers," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals. "By continuing to shine a light on the amazing contributions of young Connecticut women, The Connecticut Women's Hall of Fame is ensuring that these women are recognized for their impressive achievements at a local level."

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. Radezolid (RX-1741), an oxazolidinone, is an oral/IV agent for treatment of serious Gram-positive infections. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococus pneumonia and S. pyogenes. Additionally, Rib-X is developing delafloxacin, (RX-3341), an anionic fluoroquinolone active against a broad spectrum of bacteria, including quinolone-resistant Gram-positive bacteria and MRSA. Both radezolid and delafloxacin are currently in Phase 2 clinical trials.

For more information on the Rib-X mission and the pipeline, please visit the Company website at http://www.rib-x.com.

About The Connecticut Women's Hall of Fame

The Connecticut Women's Hall of Fame is an educational outreach organization whose mission is to honor publicly the achievement of Connecticut women, preserve their stories, educate the public and inspire the continued achievements of women and girls. Founded in 1994 in Hartford, Connecticut, the Hall fills the void that traditional curricula still fail to address and today stands as the state's premier source for women's history with over 85 Inductees. These women's lives and accomplishments are celebrated and documented through a wide spectrum of innovative statewide programs offered free of charge to Connecticut citizens. The CWHF Website, which is an educational tool receiving more than 100,000 individual visits each year, attracts international, national and local researchers, teachers and students. For more information please visit http://www.cwhf.org.


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Susan Lark, MD Says "Volunteer" Your Way to Good Health this Holiday Season
2. Susan G. Komen Breast Cancer Foundation awards grant for imaging-agent research
3. Susan Lark, MD Offers 5 Tips for Managing Stress During Tough Economic Times
4. Susan G. Komen for the Cure(R) Strengthens Global Mission With Addition of Vice President, International
5. DownEast Outfitters Supports Susan G. Komen for the Cure(R) with Breast Cancer Awareness Event and Donation
6. Susan G. Komen for the Cure(R) Advocacy Alliance Unveils New I Vote for the Cure(R) Web Video
7. Susan Lark, MD Develops a Powerful ORAC Drink Packed with the Antioxidant Power of Nine Fruits
8. New Specialty Hospital Dedicated in Ghana is Key Component of Susan G. Komen for the Cure(R)s Debut in Africa
9. Stronger Together: The Mohawk Group Supports Breast Cancer Awareness with T-Shirts Designed by Todd Oldham, Proceeds to Benefit Susan G. Komen
10. Supporting Susan G. Komen for the Cure(R) During National Breast Cancer Awareness Month
11. Purina(R) Cat Chow(R) Brand Cat Food Partners With Susan G. Komen for the Cure(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 ... ... Company, Cal Dining at the University of California Berkeley, and other leading institutions ... leverages the buying power of institutions to change the way animals are raised ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology: